PURPOSE: TAX 324 was a phase III trial comparing induction chemotherapy (IC) with docetaxel, cisplatin, and fluorouracil (TPF) with cisplatin and fluorouracil (PF) followed by concomitant chemoradiotherapy in locally advanced squamous cell cancer of the head and neck (LASCCHN). This study evaluates a series of tumor markers in pretreatment biopsies from that trial TAX 324 and correlates expression with survival. METHODS: Pretherapy biopsy specimens were available for 265 of 501 participants. Expression of a series of six markers (p53, thymidylate synthase, glutathione s-transferase pi [GST-pi], Bcl 2, beta tubulin II [betaT-2], and HER2 neu) was evaluated by immunohistochemistry. RESULTS: For patients with low betaT-II expression, median overall survival (OS) was 58.6 months (95% CI, not reached [NR]), compared with 18.2 months for patients with high betaT-II expression (95% CI, 13.11 to 30.06: hazard ratio [HR], 2.39; 95% CI, 1.67 to 3.72; P < .0001). Progression-free survival in patients with low betaT-II expression was 43.2 months (95% CI, 24.4 to NR) versus 9.8 months (95% CI, 7.06 to 18.53) for high betaT-II expression, with a HR of 1.9 (95% CI, 1.43 to 2.77; P < .0001). The predictive value of betaT-II expression was greater in the TPF versus PF arm than in the PF arm. CONCLUSION: Increased tumor expression of betaT-II is strongly associated with adverse outcome in LASCCHN patients treated with IC, and our data suggest low expression of betaT-II may predict patients most likely to benefit from induction TPF therapy. Further, simple models which combine expression of betaT-II with a carefully defined set of additional immunohistochemical markers may have significant prognostic impact for patients with LASCCHN.
RCT Entities:
PURPOSE: TAX 324 was a phase III trial comparing induction chemotherapy (IC) with docetaxel, cisplatin, and fluorouracil (TPF) with cisplatin and fluorouracil (PF) followed by concomitant chemoradiotherapy in locally advanced squamous cell cancer of the head and neck (LASCCHN). This study evaluates a series of tumor markers in pretreatment biopsies from that trial TAX 324 and correlates expression with survival. METHODS: Pretherapy biopsy specimens were available for 265 of 501 participants. Expression of a series of six markers (p53, thymidylate synthase, glutathione s-transferase pi [GST-pi], Bcl 2, beta tubulin II [betaT-2], and HER2 neu) was evaluated by immunohistochemistry. RESULTS: For patients with low betaT-II expression, median overall survival (OS) was 58.6 months (95% CI, not reached [NR]), compared with 18.2 months for patients with high betaT-II expression (95% CI, 13.11 to 30.06: hazard ratio [HR], 2.39; 95% CI, 1.67 to 3.72; P < .0001). Progression-free survival in patients with low betaT-II expression was 43.2 months (95% CI, 24.4 to NR) versus 9.8 months (95% CI, 7.06 to 18.53) for high betaT-II expression, with a HR of 1.9 (95% CI, 1.43 to 2.77; P < .0001). The predictive value of betaT-II expression was greater in the TPF versus PF arm than in the PF arm. CONCLUSION: Increased tumor expression of betaT-II is strongly associated with adverse outcome in LASCCHNpatients treated with IC, and our data suggest low expression of betaT-II may predict patients most likely to benefit from induction TPF therapy. Further, simple models which combine expression of betaT-II with a carefully defined set of additional immunohistochemical markers may have significant prognostic impact for patients with LASCCHN.
Authors: Yin Wu; Marshall R Posner; Lisa M Schumaker; Nikolaos Nikitakis; Olga Goloubeva; Ming Tan; Changwan Lu; Sana Iqbal; Jochen Lorch; Nicholas J Sarlis; Robert I Haddad; Kevin J Cullen Journal: Cancer Date: 2011-08-25 Impact factor: 6.860
Authors: Nabil F Saba; Kelly R Magliocca; Sungjin Kim; Susan Muller; Zhengjia Chen; Taofeek K Owonikoko; Nicholas J Sarlis; Carrie Eggers; Vanessa Phelan; William J Grist; Amy Y Chen; Suresh S Ramalingam; Zhuo G Chen; Jonathan J Beitler; Dong M Shin; Fadlo R Khuri; Adam I Marcus Journal: Head Neck Pathol Date: 2013-07-24
Authors: Jakob Schmidt Jensen; Julie Thor Christensen; Katrin Håkansson; Martin Zamani; Ivan R Vogelius; Johan Löfgren; Babara Malene Fischer; Jeppe Friborg; Christian von Buchwald; Jacob Høygaard Rasmussen Journal: Eur J Nucl Med Mol Imaging Date: 2019-11-13 Impact factor: 9.236
Authors: Luis J Leandro-García; Susanna Leskelä; Carlos Jara; Henrik Gréen; Elisabeth Avall-Lundqvist; Heather E Wheeler; M Eileen Dolan; Lucia Inglada-Perez; Agnieszka Maliszewska; Aguirre A de Cubas; Iñaki Comino-Méndez; Veronika Mancikova; Alberto Cascón; Mercedes Robledo; Cristina Rodríguez-Antona Journal: Clin Cancer Res Date: 2012-06-20 Impact factor: 12.531
Authors: Mei-Kim Ang; Mihir R Patel; Xiao-Ying Yin; Sneha Sundaram; Karen Fritchie; Ni Zhao; Yufeng Liu; Alex J Freemerman; Matthew D Wilkerson; Vonn Walter; Mark C Weissler; William W Shockley; Marion E Couch; Adam M Zanation; Trevor Hackman; Bhishamjit S Chera; Stephen L Harris; C Ryan Miller; Leigh B Thorne; Michele C Hayward; William K Funkhouser; Andrew F Olshan; Carol G Shores; Liza Makowski; D Neil Hayes Journal: Clin Cancer Res Date: 2011-09-09 Impact factor: 12.531